Investigational drug · Phase 3
Atirmociclib
Also called: PF-07220060
Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
9
8 still active
All registered trials
9
Any phase or sponsor naming "Atirmociclib"
First trial start
2018
Mar 30, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Atirmociclib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Breast Cancer
- Advanced Breast Cancer
- Metastatic Breast Cancer
- Locally Advanced or Metastatic ER+ HER2- Breast Cancer
- Locally Advanced or Metastatic Castration-resistant Prostate Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Solid Tumors
- Early Breast Cancer
- Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-)
- Liposarcoma
Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Prostate cancer · Sarcoma · Oncology · Kidney and urology · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "Atirmociclib" as an intervention, largest first.
- A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast CancerPivotal-lookingNot yet recruiting
PfizerPfizer (PFE)
NCT07890597 · 3,800 participants (planned) · Start Dec 1, 2026 · Primary completion Apr 13, 2032
Drug: Atirmociclib; giredestrant · For: Early Breast Cancer; Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-)
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03424005 · 1,132 participants (planned) · Start Mar 30, 2018 · Primary completion Sep 30, 2030
Drug: Capecitabine; Atezolizumab and 21 more · For: Metastatic Breast Cancer
Sites: Duarte, California; Irvine, California; La Jolla, California · 55 sites in all
- A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid TumorsNot yet recruiting
PfizerPfizer (PFE)
NCT07897721 · 268 participants (planned) · Start Nov 9, 2026 · Primary completion Mar 22, 2030
Drug: PF-08165784; Fulvestrant and 3 more · For: Advanced Breast Cancer; Advanced or Metastatic Breast Cancer; Metastatic Breast Cancer (HR+/ HER2-) and 1 more
Sites: Fayetteville, Arkansas; Rogers, Arkansas; Springdale, Arkansas · 5 sites in all
- First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast CancerPivotal-lookingActive, not recruiting
OnKure, Inc.Industry
NCT06239467 · 200 participants (planned) · Start Feb 26, 2024 · Primary completion Dec 31, 2026
Drug: OKI-219; Fulvestrant and 4 more · For: Advanced Cancer; Breast Cancer; Advanced Solid Tumors and 1 more
Sites: Encinitas, California; La Jolla, California; Los Angeles, California · 33 sites in all
- Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast CancerActive, not recruiting
Olema Oncology, Inc.Industry
NCT05508906 · 190 participants (planned) · Start Aug 31, 2022 · Primary completion Dec 31, 2027
Drug: Palazestrant; Ribociclib and 3 more · For: Metastatic Breast Cancer; ER-positive Breast Cancer; HER2-negative Breast Cancer and 2 more
Sites: Gilbert, Arizona; San Francisco, California; Aurora, Colorado · 16 sites in all
PfizerPfizer (PFE)
NCT07215078 · 72 participants · Start Oct 8, 2025 · Primary completion Jul 21, 2026
Drug: atirmociclib (PF-07220060) · For: Healthy Volunteer
Sites: New Haven, Connecticut
- A Study to Compare Two Tablet Formulations of Study Medicine Atirmociclib in Healthy ParticipantsPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT07130097 · 35 participants · Start Aug 14, 2025 · Primary completion Oct 26, 2025
Drug: PF-07220060 · For: Healthy Participant
Sites: New Haven, Connecticut
PfizerPfizer (PFE)
NCT07677358 · 28 participants (planned) · Start Jun 29, 2026 · Primary completion Aug 14, 2027
Drug: Atirmociclib · For: Hepatic Impairment; Healthy, Hepatic Insufficiency; Healthy Adults
Sites: Miami Lakes, Florida; Orlando, Florida; Tampa, Florida
AstraZenecaAstraZeneca (AZN)
NCT07427394 · 24 participants (planned) · Start May 6, 2026 · Primary completion Dec 28, 2027
Drug: Camizestrant; Atirmociclib · For: Advanced Breast Cancer
Sites: St Louis, Missouri; East Providence, Rhode Island; Nashville, Tennessee · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Identification of benzoxazine scaffold derivatives as novel CDK4 inhibitors for the treatment of cancer.
Lin C, Sun S, Zhang H, et al. · J Enzyme Inhib Med Chem 2026
- Corrigendum to "Development and ICH M10-compliant validation of an LC-MS/MS method for quantification of Atirmociclib in mouse plasma and its application to preclinical pharmacokinetic studies" [J. Chromatogr. B 1284 (2026) 125271].
Gaur A, Patel U, Gavali A, et al. · J Chromatogr B Analyt Technol Biomed Life Sci 2026
- Development and ICH M10-compliant validation of an LC-MS/MS method for quantification of atirmociclib in mouse plasma and its application to preclinical pharmacokinetic studies.
Gaur A, Patel U, Gavali A, et al. · J Chromatogr B Analyt Technol Biomed Life Sci 2026
- Atirmociclib and fulvestrant for patients with HR-positive/HER2-negative advanced or metastatic breast cancer who progressed on a prior cyclin-dependent kinase 4/6 inhibitor: primary analysis of the randomized FourLight-1 trial.
Giordano A, Xu B, Yoshinami T, et al. · Ann Oncol 2026
- Design, synthesis, molecular modeling and anti-cancer activity of novel fluorinated naphtho[2,3-b]thiophene-4,9-dione derivatives.
Nguyen HT, Hoang Thi P, Dang Thi TA, et al. · RSC Adv 2026
- CDK4-selective inhibitor AU2-94 for the treatment of advanced and therapy-resistant prostate cancer.
Safaroghli-Azar A, Croft T, Mekonnen LB, et al. · J Exp Clin Cancer Res 2026
Also in development for Breast Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- JSKN003Phase 37 trials
Shanghai JMT-Bio Inc. · HER2-positive Colorectal Cancer, Advanced Solid Tumor, HER2-positive Gastric Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Pfizer.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.